{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T02:55:07Z","timestamp":1791860107763,"version":"4.3.4"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016912","name":"Merck Sharp and Dohme France","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016912","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontierspartnerships.org"],"crossmark-restriction":true},"short-container-title":["Transpl. Int."],"abstract":"<jats:p>The incidence of leukopenia and neutropenia associated with cytomegalovirus (CMV) prophylaxis in kidney transplant (KT) recipients is not well established. LECOCYT, a prospective observational multicenter study, aimed to investigate the clinical and economic burdens of CMV prophylaxis during the first 6\u00a0months post-transplantation. Grade 3 or 4 leukopenia or neutropenia was assessed in CMV-seropositive donors\/CMV-seronegative recipients (D+\/R-) who received current anti-CMV prophylaxis, and in CMV-seronegative donors\/CMV-seronegative recipients (D-\/R-) who did not. The economic burden in D+\/R- was also evaluated. The adjusted odds ratio for grade 3 or 4 leukopenia or neutropenia was 5.16 [95% confidence interval: 1.97\u201313.53] for D+\/R- group. The median costs, excluding the KT procedure, for D+\/R- subgroup patients who experienced at least one episode of severe leukopenia or neutropenia were approximately \u20ac4,500 (Q1 = \u20ac561; Q3 = \u20ac10,000). D+\/R- patients with no episode incurred significantly lower costs, with a median of nearly \u20ac2,100 (Q1 = \u20ac182; Q3 = \u20ac6,500) (p = 0.02). D+\/R- patients with severe leukopenia or neutropenia had a higher rate of outpatient consultations than those without episode (73.9% vs. 57.6%, p = 0.002), and a higher average number of consultations per patient (5.5 \u00b1 4.1 vs. 4.5 \u00b1 3.3, p = 0.042) than D+\/R- patients without. Anti-CMV prophylaxis in D+\/R- transplant recipients was significantly associated with a higher rate of severe leukopenia or neutropenia compared to no prophylaxis in D-\/R- recipients.<\/jats:p>","DOI":"10.3389\/ti.2025.14342","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T10:23:52Z","timestamp":1747650232000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical and Economic Burden Associated With Anti-Cytomegalovirus (CMV) Prophylaxis Therapies in Adult Kidney Transplant Recipients (LECOCYT): An Observational Study"],"prefix":"10.3389","volume":"38","author":[{"given":"Nassim","family":"Kamar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Kaminski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Masset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Castagn\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilhem","family":"Tournaire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Bourge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Bensimon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moustafa","family":"Naja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Degroote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Durand-Zaleski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Legendre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1093\/ajhp\/62.suppl_1.S7","article-title":"Epidemiology of Cytomegalovirus Disease in Solid Organ and Hematopoietic Stem Cell Transplant Recipients","volume":"62","author":"Razonable","year":"2005","journal-title":"Am J Health Syst Pharm"},{"key":"B2","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1097\/tp.0000000000002191","article-title":"The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-Organ Transplantation","volume":"102","author":"Kotton","year":"2018","journal-title":"Transplantation"},{"key":"B3","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1111\/ajt.14208","article-title":"Infection in Organ Transplantation","volume":"17","author":"Fishman","year":"2017","journal-title":"Am J Transpl"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e13512","DOI":"10.1111\/ctr.13512","article-title":"Cytomegalovirus in Solid Organ Transplant Recipients-Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice","volume":"33","author":"Razonable","year":"2019","journal-title":"Clin Transpl"},{"key":"B5","doi-asserted-by":"publisher","first-page":"10332","DOI":"10.3389\/ti.2022.10332","article-title":"Cytomegalovirus Management in Solid Organ Transplant Recipients: A Pre-COVID-19 Survey from the Working Group of the European Society for Organ Transplantation","volume":"35","author":"Grossi","year":"2022","journal-title":"Transpl Int"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1111\/j.1600-6143.2009.02699.x","article-title":"Incidence, Risk Factors and Clinical Consequences of Neutropenia Following Kidney Transplantation: A Retrospective Study","volume":"9","author":"Zafrani","year":"2009","journal-title":"Am J Transpl"},{"key":"B7","doi-asserted-by":"publisher","first-page":"100587","DOI":"10.1016\/j.trre.2020.100587","article-title":"Antiviral Treatment Approaches for Cytomegalovirus Prevention in Kidney Transplant Recipients: A Systematic Review of Randomized Controlled Trials","volume":"35","author":"Raval","year":"2021","journal-title":"Transpl Rev (Orlando)"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1056\/nejm199905133401903","article-title":"Valacyclovir for the Prevention of Cytomegalovirus Disease after Renal Transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group","volume":"340","author":"Lowance","year":"1999","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1097\/00007890-199712270-00036","article-title":"Prophylactic Oral Ganciclovir Compared with Deferred Therapy for Control of Cytomegalovirus in Renal Transplant Recipients","volume":"64","author":"Brennan","year":"1997","journal-title":"Transplantation"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3621","DOI":"10.1016\/s0041-1345(01)02558-1","article-title":"Preemptive Oral Ganciclovir Therapy versus Prophylaxis to Prevent Symptomatic Cytomegalovirus Infection after Kidney Transplantation","volume":"33","author":"Jung","year":"2001","journal-title":"Transpl Proc"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1681\/asn.2012010100","article-title":"Long-term Outcomes of Pre-emptive Valganciclovir Compared with Valacyclovir Prophylaxis for Prevention of Cytomegalovirus in Renal Transplantation","volume":"23","author":"Reischig","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1111\/j.1600-6143.2007.02133.x","article-title":"Improvement in Long-Term Renal Graft Survival Due to CMV Prophylaxis with Oral Ganciclovir: Results of a Randomized Clinical Trial","volume":"8","author":"Kliem","year":"2008","journal-title":"Am J Transpl"},{"key":"B13","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/TP.0b013e318238dab3","article-title":"Valganciclovir Prophylaxis versus Preemptive Therapy in Cytomegalovirus-Positive Renal Allograft Recipients: 1-year Results of a Randomized Clinical Trial","volume":"93","author":"Witzke","year":"2012","journal-title":"Transplantation"},{"key":"B14","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1001\/jama.2023.9106","article-title":"Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients: A Randomized Clinical Trial","volume":"330","author":"Limaye","year":"2023","journal-title":"Jama"},{"key":"B15","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/ajt.12103","article-title":"Cytomegalovirus in Solid Organ Transplantation","volume":"13","author":"Razonable","year":"2013","journal-title":"Am J Transpl"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e14227","DOI":"10.1111\/tid.14227","article-title":"Incidence of Valganciclovir-Related Leukopenia and Neutropenia in Solid Organ Transplant Recipients at High Risk of Cytomegalovirus Disease","volume":"26","author":"Belga","year":"2024","journal-title":"Transpl Infect Dis"},{"key":"B17","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/j.1600-6143.2011.03766.x","article-title":"High Incidence of Anticytomegalovirus Drug Resistance Among D+R-Kidney Transplant Recipients Receiving Preemptive Therapy","volume":"12","author":"Couzi","year":"2012","journal-title":"Am J Transpl"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12732","article-title":"Burden of Cytomegalovirus Disease in Solid Organ Transplant Recipients: A National Matched Cohort Study in an Inpatient Setting","volume":"19","author":"Hakimi","year":"2017","journal-title":"Transpl Infect Dis"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1097\/00007890-199306000-00013","article-title":"The Cost Impact of Cytomegalovirus Disease in Renal Transplant Recipients","volume":"55","author":"McCarthy","year":"1993","journal-title":"Transplantation"}],"container-title":["Transplant International"],"original-title":[],"link":[{"URL":"https:\/\/www.frontierspartnerships.org\/articles\/10.3389\/ti.2025.14342\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T10:23:53Z","timestamp":1747650233000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontierspartnerships.org\/articles\/10.3389\/ti.2025.14342\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,19]]},"references-count":19,"alternative-id":["10.3389\/ti.2025.14342"],"URL":"https:\/\/doi.org\/10.3389\/ti.2025.14342","relation":{},"ISSN":["1432-2277"],"issn-type":[{"value":"1432-2277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,19]]},"article-number":"14342"}}